Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)
Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)
The purpose of this study is to determine the efficacy of ertapenem sodium (Invanz) in
 treatment of complicated urinary tract infections with respect to the proportion of patients
 with a favorable microbiological response at 5-9 days post therapy.
Inclusion Criteria:

 -  Adult patients with a suspected or documented complicated urinary tract infection

 -  Female patients must test negative for pregnancy and agree to use adequate birth
 control measures

 -  Nursing women must agree to defer breastfeeding until 5 days after completion of all
 study antibiotic therapy

 Exclusion Criteria:

 -  Patients with complete obstruction of any portion of the urinary tract

 -  Patients with rapidly progressive or terminal illness

 -  Renal transplant patients